SC
HRMY icon

Stephens Consulting’s Harmony Biosciences HRMY Stock Holding History

Stephens Consulting’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$332 – 1546
2025
Q1 		$332 Buy
+10
New +$358 ﹤0.01% 1417

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stephens Consulting's HRMY Position: Q2 2025 in Review

Stephens Consulting sold out of Harmony Biosciences (HRMY) in Q2 2025, closing a stake of 10 shares — an estimated $332 sold.

Stephens Consulting first reported a position in HRMY in Q1 2025 and held it in 1 quarter. The position peaked at $332 in Q1 2025. 279 funds tracked by Wall St. Rank hold HRMY as of Q2 2025.

  • Stephens Consulting reported no remaining Harmony Biosciences position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 10 Harmony Biosciences shares in Q2 2025, an estimated $332.
  • Stephens Consulting first reported a position in Harmony Biosciences in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Harmony Biosciences position peaked at $332 in Q1 2025.
  • 279 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.